A Combination of Savolitinib and Osimertinib Prolongs PFS in Patients with EGFR-mutated NSCLC and Acquired MET Amplification After Progression On a First-Line EGFR TKI By Ogkologos - January 16, 2026 498 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the SACHI study Source RELATED ARTICLESMORE FROM AUTHOR A glucometer for cancer: towards a scalable, universal residual disease measurement Consensus-Defined Weight Loss Episodes Arise in Discrete Intervals, Are Enriched Around Progression and Associated with Serologic Signatures and Somatic Tumour Genotypes ESMO launches new principles for humanising scientific reporting to strengthen the communication of cancer research MOST POPULAR EMA Recommends Granting a Marketing Authorisation for Lenalidomide Mylan October 23, 2020 Adding Atezolizumab to Chemotherapy Does Not Improve Outcomes in Patients Who... June 4, 2024 Breaking News: Medical Debt and Your Credit Report March 23, 2022 Can Chemotherapy Drugs Be Designed to Avoid Side Effects? December 16, 2022 Load more HOT NEWS ESMO Calls on EU Research Ministers to Prioritise Cancer Research Funding... Carriers of a Germline Pathogenic Variant in CDKN2A are at a... Cancer in My Community: Working to Eliminate the Stigma of Cancer... BRCA Gene Testing: Risks, Benefits, Costs, and Coverage
